Cao, Enyuan http://orcid.org/0000-0002-9689-4517
Watt, Matthew J.
Nowell, Cameron J. http://orcid.org/0000-0002-8662-9840
Quach, Tim
Simpson, Jamie S.
De Melo Ferreira, Vilena
Agarwal, Sonya
Chu, Hannah
Srivastava, Anubhav http://orcid.org/0000-0003-4802-2404
Anderson, Dovile http://orcid.org/0000-0003-0284-471X
Gracia, Gracia
Lam, Alina
Segal, Gabriela
Hong, Jiwon http://orcid.org/0000-0003-0936-3281
Hu, Luojuan
Phang, Kian Liun
Escott, Alistair B. J.
Windsor, John A.
Phillips, Anthony R. J.
Creek, Darren J. http://orcid.org/0000-0001-7497-7082
Harvey, Natasha L.
Porter, Christopher J. H. http://orcid.org/0000-0003-3474-7551
Trevaskis, Natalie L. http://orcid.org/0000-0001-9538-549X
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1100036, 1100036, 1100036, 1177084, 1100036, 1100036)
Hugo Charitable Trust, New Zealand
New Zealand Health Research Council 16-036
Article History
Received: 25 February 2020
Accepted: 13 August 2021
First Online: 20 September 2021
Competing interests
: C.J.H.P., N.L.T., T.Q., J.S.S., E.C. and M.J.W. are inventors of the lymph-directing glyceride prodrug technology described in the text (PCT/AU2020/050997). This technology has been patented and licensed via a commercial agreement with PureTech Health. PureTech Health has subsequently entered into a collaboration agreement with Boehringer Ingelheim to explore the technology in immune modulation. J.S.S. and T.Q. are currently employed by PureTech Health. The remaining authors declare no competing interests.